• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服中成药联合西药治疗稳定型心绞痛的比较效果:一项对179项试验的系统评价和网状Meta分析

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials.

作者信息

Huang Peiying, Li Zhishang, Chen Li, Zeng Jing, Zhao Shuai, Tang Yong, Huang Bixuan, Guan Hansu, Chen Yan, Feng Yuchao, Lei Sisi, Wu Qihua, Zhang Haobo, Huang Xiaoyan, Zeng Linsheng, Liu Yuxiang, Zeng Zhongyi, Chen Bojun

机构信息

The Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China.

Emergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.

出版信息

Front Pharmacol. 2022 Aug 17;13:918689. doi: 10.3389/fphar.2022.918689. eCollection 2022.

DOI:10.3389/fphar.2022.918689
PMID:36059992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9428755/
Abstract

Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534.

摘要

稳定型心绞痛是一种发病率和死亡率都很高的常见病症。据报道,口服中成药(OCPMs)与西药(WM)联合使用可能比单独使用西药取得更好的效果。然而,用于稳定型心绞痛的最佳中成药仍存在争议,值得进一步的实证研究。检索了PubMed、Embase、Web of Science、Cochrane图书馆、Ovid-Medline、ClinicalTrials.gov、中国知网、万方数据库、维普期刊数据库和中国生物医学文献数据库,检索时间从建库至2022年3月13日。我们使用Cochrane偏倚风险工具(ROB2)第2版来评估所选研究的整体质量。我们还使用R 4.1.2和STATA 14.0软件进行网络荟萃分析,随后进行敏感性和亚组分析。共纳入179项随机对照试验,涉及16789例患者。所选试验均被评估为存在一些问题。中成药与西药联合使用比单独使用西药具有更好的治疗效果。在有效临床率方面,与参松养心胶囊(SSYX)+西药、麝香保心丸(SXBX)+西药、通心络胶囊(TXL)+西药、血府逐瘀胶囊(XFZY)+西药、芪苈强心胶囊(QLQX)+西药、脑心通胶囊(NXT)+西药、复方丹参滴丸(FFDS)+西药和丹蒌片(DL)+西药相比,发现芪参益气滴丸(QSYQ)+西药有显著提高。QSYQ +西药具有最高的排序概率(98.12%)。在心电图有效率方面,QSYQ +西药优于SXBX +西药、TXL +西药、DL +西药、FFDS +西药和NXT +西药。QSYQ +西药排名第一(94.21%)。在心绞痛每周发作频率方面,QLQX +西药比FFDS +西药、宽胸气雾剂(KXQW)+西药、NXT +西药、QLQX +西药、SSYX +西药、SXBX +西药和TXL +西药取得更好的效果。QLQX +西药排名第一(100.00%)。在心绞痛发作持续时间方面,KXQW +西药优于SSYX +西药;KXQW +西药排名第一(95.71%)。在每周硝酸甘油使用量方面,TXL +西药具有最高的排序概率(82.12%)。在心血管事件发生率方面,DL +西药效果最高(73.94%)。此外,SSYX +西药的药物不良反应发生率最低(1.14%)。中成药与西药联合使用具有更高的疗效。QSYQ +西药、QLQX +西药、KXQW +西药、TXL +西药、DL +西药、SSYX +西药和SXBX +西药值得进一步研究。SXBX +西药可能是临床疗效和心血管事件发生率方面的最佳治疗方剂。需要进一步高质量的实证研究来证实当前结果。网址 = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534,CRD 42022316534

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/8ce1caed2e42/fphar-13-918689-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/9c71100b00b1/fphar-13-918689-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/ad85f1aa827b/fphar-13-918689-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/6c4c2b73f7c6/fphar-13-918689-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/e1ad3711d31d/fphar-13-918689-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/8ce1caed2e42/fphar-13-918689-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/9c71100b00b1/fphar-13-918689-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/ad85f1aa827b/fphar-13-918689-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/6c4c2b73f7c6/fphar-13-918689-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/e1ad3711d31d/fphar-13-918689-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db0d/9428755/8ce1caed2e42/fphar-13-918689-g005.jpg

相似文献

1
The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials.口服中成药联合西药治疗稳定型心绞痛的比较效果:一项对179项试验的系统评价和网状Meta分析
Front Pharmacol. 2022 Aug 17;13:918689. doi: 10.3389/fphar.2022.918689. eCollection 2022.
2
Comparative efficacy of eight oral Chinese patent medicines for dilated cardiomyopathy with heart failure: a Bayesian network meta-analysis.八种口服中药治疗心力衰竭扩张型心肌病的疗效比较:贝叶斯网状Meta 分析。
Syst Rev. 2024 Aug 31;13(1):222. doi: 10.1186/s13643-024-02582-5.
3
A Five-Dimensional Network Meta-Analysis of Chinese Herbal Injections for Treating Acute Tonsillitis Combined With Western Medicine.中药注射剂联合西药治疗急性扁桃体炎的五维网状Meta分析
Front Pharmacol. 2022 Jun 17;13:888073. doi: 10.3389/fphar.2022.888073. eCollection 2022.
4
Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis.商业口服多草药中药配方联合西药治疗良性前列腺增生的比较疗效:一项系统评价和网状Meta分析
Front Pharmacol. 2024 Jun 5;15:1358340. doi: 10.3389/fphar.2024.1358340. eCollection 2024.
5
[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].[中成药治疗慢性肺源性心脏病的网状Meta分析]
Zhongguo Zhong Yao Za Zhi. 2024 Jul;49(14):3936-3951. doi: 10.19540/j.cnki.cjcmm.20240318.501.
6
[Network Meta-analysis of Chinese patent medicines in treatment of coronary heart disease complicated with heart failure].[中成药治疗冠心病合并心力衰竭的网络Meta分析]
Zhongguo Zhong Yao Za Zhi. 2024 Jan;49(2):518-533. doi: 10.19540/j.cnki.cjcmm.20231014.501.
7
The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials.中文专利药治疗非增殖性糖尿病视网膜病变的比较效果:一项基于随机对照试验的贝叶斯网状 Meta 分析。
Front Endocrinol (Lausanne). 2023 Apr 3;14:1144290. doi: 10.3389/fendo.2023.1144290. eCollection 2023.
8
Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis.脑心通胶囊联合西药对经皮冠状动脉介入术后冠心病的综合疗效:一项Meta分析
Front Pharmacol. 2024 Mar 25;15:1274000. doi: 10.3389/fphar.2024.1274000. eCollection 2024.
9
[Network Meta-analysis of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris].[益气活血类中成药治疗冠心病心绞痛的网状Meta分析]
Zhongguo Zhong Yao Za Zhi. 2019 May;44(9):1927-1937. doi: 10.19540/j.cnki.cjcmm.20190114.001.
10
[Network Meta-analysis of Chinese patent medicine in treatment of unstable angina pectoris].[中成药治疗不稳定型心绞痛的网络Meta分析]
Zhongguo Zhong Yao Za Zhi. 2021 Feb;46(3):703-711. doi: 10.19540/j.cnki.cjcmm.20201103.502.

引用本文的文献

1
Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2.利用超级计算多配体建模、模拟、小波分析和表面等离子体共振开发新型联合药物:以阿比朵尔和黄芩苷抗SARS-CoV-2主要蛋白酶为例
Pharmaceuticals (Basel). 2025 Jul 17;18(7):1054. doi: 10.3390/ph18071054.
2
A Direct Relationship Between 'Blood Stasis' and Fibrinaloid Microclots in Chronic, Inflammatory, and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment.慢性炎症性和血管性疾病中“血瘀”与类纤维蛋白微血栓的直接关系及一些传统天然产物治疗方法
Pharmaceuticals (Basel). 2025 May 12;18(5):712. doi: 10.3390/ph18050712.
3

本文引用的文献

1
Pharmacodynamic Mechanism of Kuanxiong Aerosol for Vasodilation and Improvement of Myocardial Ischemia.宽胸气雾剂扩张血管和改善心肌缺血的药效学机制。
Chin J Integr Med. 2022 Apr;28(4):319-329. doi: 10.1007/s11655-021-2882-z. Epub 2021 Dec 12.
2
Danlou Tablet Activates Autophagy of Vascular Adventitial Fibroblasts Through PI3K/Akt/mTOR to Protect Cells From Damage Caused by Atherosclerosis.丹蒌片通过PI3K/Akt/mTOR激活血管外膜成纤维细胞自噬,以保护细胞免受动脉粥样硬化所致损伤。
Front Pharmacol. 2021 Nov 18;12:730525. doi: 10.3389/fphar.2021.730525. eCollection 2021.
3
Diagnosis and Management of Stable Angina: A Review.
Comparative efficacy of topical commercial Chinese polyherbal preparation for vulvovaginal candidiasis: a network meta-analysis.局部应用商业性中药复方制剂治疗外阴阴道念珠菌病的疗效比较:网状Meta分析
Front Pharmacol. 2025 Feb 3;16:1484325. doi: 10.3389/fphar.2025.1484325. eCollection 2025.
4
Clinical observation of Danlou tablets combined with aspirin for phlegm and blood stasis syndrome in coronary heart disease: impact on related serum factors.丹蒌片联合阿司匹林治疗冠心病痰瘀互结证的临床观察:对相关血清因子的影响
Am J Transl Res. 2024 Nov 15;16(11):6812-6820. doi: 10.62347/WMBN8994. eCollection 2024.
5
Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications.参松养心——一种用于治疗心律失常的多功能中药:成分、药理机制及临床应用综述
Heliyon. 2024 Aug 2;10(16):e35560. doi: 10.1016/j.heliyon.2024.e35560. eCollection 2024 Aug 30.
6
Exploring acupuncture as a treatment for insomnia in perimenopausal women with stable angina pectoris: A protocol for a randomized, double-blind, placebo-controlled clinical trial.探讨针灸治疗围绝经期伴稳定型心绞痛失眠症的疗效:一项随机、双盲、安慰剂对照临床试验方案。
PLoS One. 2024 Apr 18;19(4):e0301827. doi: 10.1371/journal.pone.0301827. eCollection 2024.
7
Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China.麝香保心丸(MUSKARDIA)作为标准治疗的附加治疗用于中国稳定型冠状动脉疾病的成本效果分析。
PLoS One. 2024 Mar 1;19(3):e0299236. doi: 10.1371/journal.pone.0299236. eCollection 2024.
8
Integrated Chinese and Western medicine for stable angina pectoris of coronary heart disease: a real-world study including 690 patients.中西医结合治疗冠心病稳定型心绞痛:一项纳入690例患者的真实世界研究。
Front Cardiovasc Med. 2023 May 19;10:1194082. doi: 10.3389/fcvm.2023.1194082. eCollection 2023.
稳定型心绞痛的诊断与治疗:综述。
JAMA. 2021 May 4;325(17):1765-1778. doi: 10.1001/jama.2021.1527.
4
QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy.芪参益气滴丸通过调控自噬改善心肌修复性纤维化。
J Cell Mol Med. 2020 Oct;24(19):11283-11293. doi: 10.1111/jcmm.15695. Epub 2020 Sep 2.
5
Qiliqiangxin Capsules Optimize Cardiac Metabolism Flexibility in Rats With Heart Failure After Myocardial Infarction.芪苈强心胶囊优化心肌梗死后心力衰竭大鼠的心脏代谢灵活性。
Front Physiol. 2020 Jul 17;11:805. doi: 10.3389/fphys.2020.00805. eCollection 2020.
6
The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond.《心血管疾病及其危险因素的全球负担:2020年及以后》
J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532. doi: 10.1016/j.jacc.2019.10.009.
7
[Shensong Yangxin Capsules in the adjuvant treatment of stable angina pectoris:a Meta-analysis and trial sequential analysis].参松养心胶囊辅助治疗稳定型心绞痛的Meta分析与试验序贯分析
Zhongguo Zhong Yao Za Zhi. 2019 Sep;44(17):3816-3824. doi: 10.19540/j.cnki.cjcmm.20190624.503.
8
RoB 2: a revised tool for assessing risk of bias in randomised trials.《随机对照试验偏倚风险评估工具2:修订版》
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
9
[Network Meta-analysis of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris].[益气活血类中成药治疗冠心病心绞痛的网状Meta分析]
Zhongguo Zhong Yao Za Zhi. 2019 May;44(9):1927-1937. doi: 10.19540/j.cnki.cjcmm.20190114.001.
10
Ethanol extracts of Danlou tablet attenuate atherosclerosis via inhibiting inflammation and promoting lipid effluent.丹鹿通痹胶囊乙醇提取物通过抑制炎症反应和促进脂质流出减轻动脉粥样硬化。
Pharmacol Res. 2019 Aug;146:104306. doi: 10.1016/j.phrs.2019.104306. Epub 2019 Jun 8.